AV 513

Drug Profile

AV 513

Alternative Names: AV513

Latest Information Update: 08 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avigen
  • Developer Baxter Healthcare Corporation
  • Class Antihaemorrhagics; Coagulants; Polysaccharides; Small molecules
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Haemophilia A; Haemophilia B

Most Recent Events

  • 18 Dec 2008 Baxter Healthcare Corporation acquires AV 513 from Avigen
  • 08 Nov 2005 Preclinical trials in Haemophilia A in USA (PO)
  • 08 Nov 2005 Preclinical trials in Haemophilia B in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top